⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600852 | 1.00 | — | — | |
| SCHEMBL18812055 | 1.00 | — | — | |
| SCHEMBL14007679 | 0.80 | — | — | |
| SCHEMBL16189235 | 0.78 | — | — | |
| SCHEMBL14997785 | 0.78 | — | — | |
| SCHEMBL30036461 | 0.78 | — | — | |
| Potassium Ion SCHEMBL15538599 | 0.72 | — | — | |
| Potassium Ion SCHEMBL15559268 | 0.72 | — | — | |
| Potassium Ion SCHEMBL15538600 | 0.72 | — | — | |
| SCHEMBL4619033 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919523-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090042973-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-7442718-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-28 | — | — | US | disclosed |
| US-7312331-B2 | Stable cyclic (alkyl)(amino) carbenes as ligands for transition metal catalysts | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070004917-A1 | Stable cyclic (alkyl)(amino) carbenes as ligands for transition metal catalysts | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2007-01-04 | — | — | US | disclosed |
| EP-1431316-B1 | The in situ polymerization of monoethylenically unsaturated monomers with oligomeric or polymeric secondary amines | BAYER MATERIALSCIENCE AG (DE) | 2006-03-22 | — | — | EP | disclosed |
| EP-1637518-A2 | Inhibitors of aspartyl protease | Vertex Pharmaceuticals Incorporated (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1159278-B1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040127488-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2004-07-01 | — | — | US | disclosed |
| US-20040122169-A1 | Situ polymerization of monoethylenically unsaturated monomers with oligomeric or polymeric secondary amines | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
| EP-1431316-A1 | The in situ polymerization of monoethylenically unsaturated monomers with oligomeric or polymeric secondary amines | Bayer MaterialScience AG (DE) | 2004-06-23 | — | — | EP | disclosed |
| EP-1428837-A1 | The in situ polymerization of monoethylenically unsaturated monomers with oligomeric or polymeric secondary amines | Bayer MaterialScience AG (DE) | 2004-06-16 | — | — | EP | disclosed |
| US-6617350-B2 | Sulfonamides which are aspartyl protease inhibitors; well suited for inhibiting HIV-1 and HIV-2 protease activity | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-09 | — | — | US | disclosed |
| US-20020198388-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-12-26 | — | — | US | disclosed |
| US-6319946-B1 | BENZODIOXOLYLSULFONAMIDES; INHIBITING HIV-1 AND HIV-2 PROTEASE ACTIVITY | VERTEX PHARMACEUTICALS INCORPORATED | 2001-11-20 | — | — | US | disclosed |
| US-4833271-A | Structurally defined oligomers and preparation thereof for the protection of oxidative phosphorylation and which exhibit ionophoretic activity | UNITED STATES OF AMERICA, THE, AS REPRESENTED BY THE NAVY DEPARTMENT | 1989-05-23 | — | — | US | disclosed |